Pancreatic Cancer - Pipeline Insight, 2022

Pancreatic Cancer - Pipeline Insight, 2022

DelveInsight’s, “Pancreatic Cancer - Pipeline Insight, 2022,” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Pancreatic Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Pancreatic Cancer Understanding

Pancreatic Cancer: Overview

Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells, pancreatic ductal carcinoma. It is the fourth leading cause of cancer deaths in the United States. The 5-year survival rate in the United States ranges from 5% to 15%. The overall survival rate is only 6%. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis. More than 90% of adenocarcinoma of the pancreas are duct cell adenocarcinomas with other types being cystadenocarcinoma and acinar cell carcinoma. Two-thirds arise in the pancreatic head; one-third arise in the rest (body and tail of pancreas). Patients with adenocarcinoma of pancreas typically present with painless jaundice (70%) usually due to obstruction of the common bile duct from the pancreatic head tumor. Weight loss occurs in about 90% of patients. Abdominal pain occurs in about 75% of patients. Weakness, pruritus from bile salts in the skin, anorexia, palpable, non-tender, distended gallbladder, acholic stools, and dark urine. Sometimes, patients may present with recurrent deep vein thrombosis (DVT) due to hypercoagulability that prompts clinicians to suspect cancer and a full workup of cancer. If adenocarcinoma of the pancreas is suspected, multidetector computed tomography, MDCT, is the best imaging modality to diagnose and evaluate the extent of disease, including perivascular extension and distant metastasis. MDCT is 77% accurate in predicting resectability and 93% accurate in predicting unresectability.

""Pancreatic Cancer - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pancreatic Cancer pipeline landscape is provided which includes the disease overview and Pancreatic Cancer treatment guidelines. The assessment part of the report embraces, in depth Pancreatic Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Pancreatic Cancer.
• In the coming years, the Pancreatic Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Pancreatic Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Pancreatic Cancer treatment market. Several potential therapies for Pancreatic Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Pancreatic Cancer market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Pancreatic Cancer) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Pancreatic Cancer Emerging Drugs Chapters

This segment of the Pancreatic Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pancreatic Cancer Emerging Drugs

• Pamrevlumab: FibroGen

Pamrevlumab is a potential first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is in Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer (LAPC), and Duchenne muscular dystrophy (DMD). The U.S. Food and Drug Administration has granted Orphan Drug Designation (ODD), and Fast Track designation to pamrevlumab for the treatment of patients with IPF, LAPC, and DMD.

• Niraparib: Innovent Biologics

Niraparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death. Increased niraparib-induced cytotoxicity was observed in tumor cell lines with or without deficiencies in BRCA1/2. Niraparib decreased tumor growth in mouse xenograft models of human cancer cell lines with deficiencies in BRCA1/2 and in human patient-derived xenograft tumor models with homologous recombination deficiency that had either mutated or wild type BRCA1/2. Currently, it is in Phase II stage of clinical trial evaluation to treat pancreatic cancer.

• CT041: CARsgen Therapeutics

CT041 is an autologous CAR T-cell product candidate against the protein CLDN18.2 that has the potential to be the first-in-class globally. CT041 targets the treatment of CLDN18.2 positive solid tumors with a primary focus on GC/GEJ and PC. CT041 has demonstrated promising therapeutic efficacy and favorable safety in ongoing clinical trials. CARsgen believes that CT041 has the potential to become a backbone therapy for GC/GEJ and PC in the future and benefit a large population of patients worldwide. Currently, it is in Phase I/II stage of clinical trial evaluation to treat pancreatic cancer.

• APG-1387: Ascentage Pharma

APG-1387 is a high-efficiency and specific inhibitor of a new generation of inhibitor of apoptosis protein (IAP) independently designed and developed by Ascentage Pharma with global intellectual property rights. It mainly induces and accelerates cell apoptosis by simulating the degradation of IAPs by endogenous SMAC molecules process. The company is developing APG-1387 globally, and has completed Phase I dose escalation trials for solid tumors in China and Australia, and is conducting Phase Ib/II clinical trials in combination with pembrolizumab in the United States. Approved to initiate a Phase Ib/II clinical trial in combination with paclitaxel and gemcitabine in the treatment of advanced pancreatic cancer in China. At the same time, the clinical study for the treatment of chronic hepatitis B is being carried out in China, and the phase II clinical study of APG-1387 combined with entecavir in the treatment of chronic hepatitis B is in progress.

• NGM120: NGM Biopharmaceuticals

NGM120 is an antagonist antibody that binds glial cell-derived neurotrophic factor receptor alpha-like (GFRAL) and inhibits growth differentiation factor 15 (GDF15) signaling. NGM initiated a Phase 2 randomized, single-blind (investigator-blinded), placebo-controlled, multi-center expansion study (PINNACLES) in March 2021 to evaluate NGM120 as a first-line treatment in 60 patients with metastatic pancreatic cancer. In the ongoing study, patients will be randomized to either NGM120 or placebo in combination with gemcitabine/Nab-paclitaxel. The study will evaluate the effects of NGM120 on both cancer and cancer-related cachexia.

Further product details are provided in the report……..

Pancreatic Cancer: Therapeutic Assessment

This segment of the report provides insights about the different Pancreatic Cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Pancreatic Cancer

There are approx. 140+ key companies which are developing the therapies for Pancreatic Cancer. The companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, FibroGen.

• Phases

DelveInsight’s report covers around 150+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pancreatic Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pancreatic Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pancreatic Cancer drugs.

Pancreatic Cancer Report Insights

• Pancreatic Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pancreatic Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pancreatic Cancer drugs?
• How many Pancreatic Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pancreatic Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Pancreatic Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pancreatic Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• FibroGen
• Innovent Biologics
• CARsgen Therapeutics
• Ascentage Pharma
• NGM Biopharmaceuticals
• TME Pharma AG
• Lee's Pharmaceutical Limited
• ImmunityBio, Inc.
• Rgene Corporation
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• CanBas Co. Ltd.
• Jiangsu HengRui Medicine Co., Ltd.
• Bristol-Myers Squibb
• SynerGene Therapeutics, Inc.
• AbbVie
• Silenseed Ltd
• Galera Therapeutics, Inc.
• Helix BioPharma
• Golden Biotechnology Corporation
• Eli Lilly and Company
• Innovent Biologics (Suzhou) Co. Ltd.
• Panbela Therapeutics, Inc.
• GlaxoSmithKline
• Chia Tai Tianqing Pharmaceutical Group
• Roche
• Prestige Biopharma Limited
• Everfront Biotech Co., Ltd.
• XBiotech, Inc.
• Incyte Corporation
• Ability Pharmaceuticals SL
• Lokon Pharma
• HCW Biologics
• Amplia Therapeutics Limited
• BioLineRx, Ltd.
• Taiho Pharmaceutical
• Sanofi
• Scandion Oncology
• Nelum
• Celldex Therapeutics
• Merus N.V.
• Seagen Inc.
• GC Cell Corporation
• MetiMedi Pharmaceuticals
• Lumicell
• Nuvation Bio Inc.
• ENB Therapeutics
• BioNTech SE

Key Products

• Pamrevlumab
• Niraparib
• CT041
• APG-1387
• BNT141
• ENB003
• NUV-868
• MCLA-128
• LUM015
• Immuncell-LC
• tisotumab vedotin
• OMT-111
• tusamitamab ravtansine
• SCO-101
• NGM120
• CDX-301
• NLM-001
• TAS 102
• Olaptesed pegol
• BL-8040
• Gimatecan
• AMP945
• N-803
• HCW9218
• BLEX 404
• delolimogene mupadenorepvec
• Mitoxantrone Hydrochloride Liposome injection
• ABTL0812
• CBP501
• Pemigatinib
• SHR-1701
• Fluzoparib
• XB2001
• Cabiralizumab
• EF-009
• SGT-53
• ABBV-927
• PBP1510
• Vemurafenib
• siG12D-LODER
• Penpulimab
• GC4711
• GSK2256098
• L-DOS47
• SBP-101
• Antroquinonol
• LY3214996
• Sintilimab